Retraction Notice to: Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder
- PMID: 35317329
- PMCID: PMC8913012
- DOI: 10.14740/wjon677wr
Retraction Notice to: Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder
Abstract
[This retracts the article DOI: 10.4021/wjon677w.].
Copyright 2022, Editorial Office.
Retraction of
-
Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder.World J Oncol. 2013 Jun;4(3):151-157. doi: 10.4021/wjon677w. Epub 2013 Jul 15. World J Oncol. 2013. Retraction in: World J Oncol. 2022 Feb;13(1):48. doi: 10.14740/wjon677wr. PMID: 29147347 Free PMC article. Retracted.
Similar articles
-
Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder.World J Oncol. 2013 Jun;4(3):151-157. doi: 10.4021/wjon677w. Epub 2013 Jul 15. World J Oncol. 2013. Retraction in: World J Oncol. 2022 Feb;13(1):48. doi: 10.14740/wjon677wr. PMID: 29147347 Free PMC article. Retracted.
-
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.J Urol. 2002 Aug;168(2):465-9. J Urol. 2002. PMID: 12131289
-
Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.Clin Chem Lab Med. 2011 Feb;49(2):311-6. doi: 10.1515/CCLM.2011.038. Epub 2010 Dec 1. Clin Chem Lab Med. 2011. PMID: 21118051
-
Non-invasive diagnostic tests for bladder cancer: a review of the literature.Urol Int. 2005;75(3):193-200. doi: 10.1159/000087792. Urol Int. 2005. PMID: 16215303 Review.
-
Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.Urology. 1995 Aug;46(2):173-7. doi: 10.1016/s0090-4295(99)80189-7. Urology. 1995. PMID: 7624989 Review.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials